SCHEMBL5467313

SCHEMBL5467313

CC(CCCS(C)(=O)=O)S(C)(=O)=O

nearest known ligand 0.34

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
TP53 P04637 2/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
CYP11B1 P15538 2/20 0.32
CYP11B2 P19099 2/20 0.32
NLRP3 Q96P20 1/20 0.32
PMP22 Q01453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5635440 0.79 LMNA (0.39) TP53ALDH1A1LMNANLRP3
SCHEMBL5637608 0.77 TP53 (0.46) TP53
SCHEMBL9662687 0.75 TP53 (0.56) TP53
SCHEMBL23686157 0.73 ALDH1A1 (0.33) TP53ALDH1A1LMNACYP11B1NLRP3
SCHEMBL11251469 0.73 PMP22 (0.38) TP53ALDH1A1LMNANLRP3PMP22
SCHEMBL17424122 0.73 TP53 (0.54) TP53LMNA
SCHEMBL17676570 0.73 TP53 (0.54) TP53LMNA
SCHEMBL15293795 0.72 LMNA (0.43) TP53ALDH1A1LMNANLRP3
SCHEMBL13192811 0.71 ALDH1A1 (0.32) TP53ALDH1A1LMNANLRP3
SCHEMBL3913999 0.71 ALDH1A1 (0.46) TP53ALDH1A1LMNANLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9064633-B2 Method for synthesizing quaternary ammonium systems HONEYWELL INTERNATIONAL INC. (US) 2015-06-23 US claimed
US-20130264510-A1 METHOD FOR SYNTHESIZING QUATERNARY AMMONIUM SYSTEMS HONEYWELL INT INC (US) 2013-10-10 US claimed
US-8426593-B2 Method for synthesizing quaternary ammonium systems HONEYWELL INTERNATIONAL INC. (US) 2013-04-23 US claimed
US-20070049750-A1 Method for synthesizing spiro quartenary ammonium systems HONEYWELL INTERNATIONAL INC. (US) 2007-03-01 US claimed
EP-0832082-B1 N-HETEROARYL-PYRIDINESULFONAMIDE DERIVATIVES AND THEIR USE AS ENDOTHELIN ANTAGONISTS ASTRAZENECA AB (SE) 2001-11-21 EP disclosed
US-6258817-B1 PRODRUGS, HYPOTENSIVE AGENTS AND CARDIOVASCULAR DISORDERS ZENECA LTD. (GB) 2001-07-10 US disclosed
US-6060475-A Substituted pyrazin-2-yl-sulphonamide-(3-pyridyl) compounds and uses thereof ZENECA LIMITED (GB) 2000-05-09 US disclosed
US-5866568-A ENDOTHELIN RECEPTOR ANTAGONIST ACTIVITY ZENECA LIMITED (GB) 1999-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049750-A1 Method for synthesizing spiro quartenary ammonium systems REN, AGT, PKD1 TP53 3100/4885ALDH1A1 2665/4885LMNA 2251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.